Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,724 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,870 Underlying: Common Stock · 18,724 shares Expires 2021-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,735 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,735 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,541 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,541 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $45.22 | $18,901.96 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 127,514 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $45.10 to $45.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,523 | $45.52 | $433,486.96 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072,205 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $45.35 to $45.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,377 | $44.92 | $421,214.84 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,081,728 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $44.35 to $45.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,724 | $3.50 | $65,534.00 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,091,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 36,735 | $2.90 | $106,531.50 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 24,541 | $3.60 | $88,347.60 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,035,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $43.64 | $18,241.52 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 127,932 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $43.35 to $44.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,829 | $44.39 | $525,089.31 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,011,105 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $44.15 to $44.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 21:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,071 | $43.66 | $308,719.86 |
DisclosureSEC source: 0001209191-17-067075 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022,934 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $43.15 to $44.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $41.49 | $17,342.82 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 128,350 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $41.20 to $41.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 300 | $42.78 | $12,834.00 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,030,005 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $42.75 to $42.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,048 | $42.07 | $338,579.36 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,030,305 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $41.725 to $42.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10,552 | $41.37 | $436,536.24 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,038,353 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $40.75 to $41.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2017 Filed Jan 3, 2018 01:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-000396 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,500 Read SEC document |
| December 15, 2017 Filed Jan 3, 2018 01:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-000396 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,071,705 Read SEC document |
| December 14, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 58 | $43.08 | $2,498.64 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 128,768 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $42.95 to $43.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 360 | $42.09 | $15,152.40 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 128,826 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $41.90 to $42.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 200 | $43.60 | $8,720.00 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048,905 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| December 14, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,782 | $43.01 | $506,743.82 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,049,105 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $42.60 to $43.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 14, 2017 Filed Dec 16, 2017 00:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,918 | $42.18 | $291,801.24 |
DisclosureSEC source: 0001209191-17-066061 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,060,887 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $41.60 to $42.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 3,261 | $44.85 | $146,255.85 |
DisclosureSEC source: 0001209191-17-064835 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,805 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| December 01, 2017 Filed Dec 6, 2017 00:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 4,689 | $47.15 | $221,086.35 |
DisclosureSEC source: 0001209191-17-064072 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,071,066 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $46.75 | $19,541.50 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 129,186 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $46.65 to $46.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,900 | $46.98 | $136,242.00 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,075,755 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $46.825 to $47.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,000 | $46.60 | $745,600.00 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,078,655 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $45.85 to $46.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $46.75 | $19,541.50 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 129,604 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $46.70 to $47.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,000 | $47.62 | $142,860.00 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,094,655 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $47.375 to $48.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,900 | $46.67 | $555,373.00 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097,655 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $46.25 to $47.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 00:05 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,000 | $45.62 | $182,480.00 |
DisclosureSEC source: 0001209191-17-061636 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,109,555 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $45.25 to $46.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $55.95 | $23,387.10 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 130,022 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,700 | $56.23 | $376,741.00 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,113,555 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $56.10 to $56.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,200 | $55.62 | $678,564.00 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,120,255 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $55.10 to $56.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10 | $56.75 | $567.50 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 130,440 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 408 | $55.82 | $22,774.56 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 130,450 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $55.65 to $56.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,200 | $57.36 | $126,192.00 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,132,455 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $57.25 to $57.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,918 | $56.65 | $561,854.70 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,134,655 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $56.25 to $57.225. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,782 | $55.79 | $378,367.78 |
DisclosureSEC source: 0001209191-17-058659 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144,573 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $55.25 to $56.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 318 | $55.25 | $17,569.50 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 130,858 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $55.10 | $5,510.00 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 131,176 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 14,700 | $55.38 | $814,086.00 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,151,355 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $55.05 to $55.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,200 | $54.69 | $229,698.00 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,166,055 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $54.00 to $55.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1 | $55.45 | $55.45 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 131,276 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 417 | $54.35 | $22,663.95 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 131,277 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $54.30 to $54.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,606 | $55.37 | $365,774.22 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,255 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $55.15 to $56.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 22:17 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,294 | $54.54 | $670,514.76 |
DisclosureSEC source: 0001209191-17-057334 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,176,861 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $54.10 to $55.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2017 Filed Oct 4, 2017 20:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $55.65 | $5,565.00 |
DisclosureSEC source: 0001209191-17-055869 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 131,694 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 03, 2017 Filed Oct 4, 2017 20:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 318 | $55.95 | $17,792.10 |
DisclosureSEC source: 0001209191-17-055869 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 131,794 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.